Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Queensland Health
UBS
AstraZeneca
Cerilliant
US Army
Johnson and Johnson
Colorcon
Moodys
Chinese Patent Office

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,172,046

« Back to Dashboard

Which drugs does patent 6,172,046 protect, and when does it expire?

Patent 6,172,046 protects REBETOL and is included in two NDAs.

Protection for REBETOL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 6,172,046
Title: Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
Abstract:There is disclosed a method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.
Inventor(s): Albrecht; Janice K. (Winter Park, FL)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:08/938,033
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,172,046

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme REBETOL ribavirin CAPSULE;ORAL 020903-001 Jun 3, 1998 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck Sharp Dohme REBETOL ribavirin CAPSULE;ORAL 020903-002 Jul 25, 2001 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Schering REBETOL ribavirin SOLUTION;ORAL 021546-001 Jul 29, 2003 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Federal Trade Commission
Dow
Teva
Daiichi Sankyo
Baxter
Colorcon
Healthtrust
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot